enGene Holdings Inc. Files 2024 10-K

TL;DR

enGene's 2024 10-K is in, check out their SPAC merger and subscription agreements.

AI Summary

enGene Holdings Inc. filed its 10-K for the fiscal year ending October 31, 2024. The company, located at 4868 Rue Levy, Suite 220, Saint-Laurent, A8, H4R 2P1, reported on its financial performance and business operations. Key financial events mentioned include subscription agreements in February 2024 and a SPAC merger with Forbion Growth Sponsor Feac I on May 16, 2023.

Why It Matters

This filing provides investors with a comprehensive overview of enGene's financial health and strategic direction for the past fiscal year, impacting investment decisions.

Risk Assessment

Risk Level: medium — The company is in the biotechnology sector, which is inherently high-risk due to long development cycles and regulatory hurdles.

Key Numbers

• 2024-10-31 — Fiscal Year End (Reporting period for the 10-K)
• 2023-10-31 — Prior Fiscal Year End (Comparison point for financial performance)
• 2022-11-01 — Start of Prior Fiscal Year (Beginning of the period covered by financial statements)

Key Players & Entities

• enGene Holdings Inc. (company) — Filer of the 10-K
• October 31, 2024 (date) — Fiscal year end
• 4868 Rue Levy, Suite 220, Saint-Laurent, A8, H4R 2P1 (address) — Company business and mail address
• February 2024 (date) — Date of subscription agreements
• Forbion Growth Sponsor Feac I (company) — SPAC partner in a merger
• May 16, 2023 (date) — Date of SPAC merger

FAQ

Key Financial Figures

• $11.50 — e Common Share, at an exercise price of $11.50 per share ENGNW The Nasdaq Stock Ma

Filing Documents

• engn-20241031.htm (10-K) — 3730KB
• engn-ex10_32.htm (EX-10.32) — 115KB
• engn-ex10_33.htm (EX-10.33) — 141KB
• engn-ex10_34.htm (EX-10.34) — 79KB
• engn-ex10_36.htm (EX-10.36) — 80KB
• engn-ex19_1.htm (EX-19.1) — 79KB
• engn-ex23_1.htm (EX-23.1) — 4KB
• engn-ex31_1.htm (EX-31.1) — 16KB
• engn-ex31_2.htm (EX-31.2) — 16KB
• engn-ex32_1.htm (EX-32.1) — 9KB
• engn-ex32_2.htm (EX-32.2) — 9KB
• engn-ex97_1.htm (EX-97.1) — 49KB
• img84713370_0.jpg (GRAPHIC) — 107KB
• img84713370_1.jpg (GRAPHIC) — 56KB
• img84713370_2.jpg (GRAPHIC) — 80KB
• img84713370_3.jpg (GRAPHIC) — 103KB
• img84713370_4.jpg (GRAPHIC) — 37KB
• img84713370_5.jpg (GRAPHIC) — 95KB
• img84713370_6.jpg (GRAPHIC) — 87KB
• img84713370_7.jpg (GRAPHIC) — 15KB
• img84713370_8.jpg (GRAPHIC) — 68KB
• img84713370_9.jpg (GRAPHIC) — 105KB
• img84713370_10.jpg (GRAPHIC) — 124KB
• img84713370_11.jpg (GRAPHIC) — 101KB
• 0000950170-24-138472.txt ( ) — 17539KB
• engn-20241031.xsd (EX-101.SCH) — 2263KB
• engn-20241031_htm.xml (XML) — 2289KB

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 26 Item 1B. Unresolved Staff Comments 82 Item 2.

Properties

Properties 82 Item 3.

Legal Proceedings

Legal Proceedings 82 Item 4. Mine Safety Disclosures 82 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 83 Item 6. [Reserved] 84 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 85 Item 7A. Quantitative and Qualitative Disclosure About Market Risk 102 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 102 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 103 Item 9A.

Controls and Procedures

Controls and Procedures 103 Item 9B. Other Information 104 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 105 PART III Item 10. Directors, Executive Officers and Corporate Governance 105 Item 11.

Executive Compensation

Executive Compensation 105 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 105 Item 13. Certain Relationships and Related Transactions, and Director Independence 105 Item 14. Principal Accountant Fees and Services 105 PART IV Item 15. Exhibits, Financial Statement Schedules 106 Item 16. Form 10-K Summary 108 SPECIAL NOTE REG ARDING FORWARD-LOOKING STATEMENTS Certain statements in this Annual Report on Form 10-K (the "Annual Report") may constitute "forward-looking statements" within the meaning of U.S. securities laws and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). enGene's forward-looking statements include, but are not limited to, statements regarding enGene's management teams' expectations, hopes, beliefs, intentions, goals or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "appear," "approximate," "believe," "continue," "could," "estimate," "expect," "foresee," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "would" and similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Annual Report may include, for example, statements about: our financial performance, including financial projections and business metrics and any underlying assumptions thereunder; our ability to maintain the listing of the Company's common shares ("Common Shares") and warrants to purchase Common Shares ("Warrants") on The Nasdaq Global Market ("Nasdaq") or another national securities exchange; our success in recruiting and re

View Full Filing

View this 10-K filing on SEC EDGAR